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Jakobsen et al.1 on the Danish Lung 
Cancer registry.
The authors describe the estab-
lishment of a national quality man-
agement system stemming from the 
development of national guidelines, 
the creation of a high-quality inte-
grated data system, frequent reports, 
and a process of audit evaluation and 
scrutiny that engages both stakeholder 
clinicians and institutions and regional 
and national health care authorities. 
Within the space of a decade, statisti-
cally and clinically important improve-
ments are demonstrated in 1-, 2-, and 
5-year survival, in addition to reduced 
waiting time, enhanced clinical and 
pathological staging concordance and 
reduction in regional variation in clini-
cal outcomes.
During this timeframe there seems 
a substantial increase in active cancer 
treatment including surgical resection, 
chemotherapy, and radiotherapy. The rate 
of potentially curative therapy, however, 
including resection rate (15%–17%) and 
rate of combined chemo-radiotherapy 
(with likely curative intent, 10%–14%) 
remained unchanged. Improved subject 
selection, characterization, and treatment 
selection are likely to improve outcomes 
in those receiving potentially curative 
treatment; however, equally appeal-
ing, yet undescribed, is the possibility 
of enhanced survival in those receiving 
treatment with noncurative intent.
Clearly the success of the initia-
tive rests on a sophisticated, informed, 
and interactive relationship between 
government, health authorities, and 
clinicians. Drivers to engagement are 
likely to include political demand and 
an important administrative recognition 
of the capability of the Danish Lung 
Cancer registry to capture necessary 
core clinical data as a mechanism to 
enable feedback and closure of the qual-
ity cycle.2 The report of similar trends 
by the national Lung Cancer Audit in 
the United Kingdom may support these 
findings.3
The pursuit of quality and safety 
in health care demands definition of 
markers that describe the structure, 
quality, and outcomes of health care 
processes.4 Although governments and 
health care providers strive to develop 
 disease-relevant and epidemiologically 
robust measures of quality there remains 
a major gap, with relatively few exam-
ples of nationwide,  population-based 
systems established for such data collec-
tion.5 The peer-reviewed publication of 
outcomes attributable to clinical quality 
registry activity does much to promote 
registry science and demonstrates a 
potentially powerful role in advancing 
safety and quality in health care out-
comes. The Danish Lung Cancer Group 
and Danish Government have provided 
significant leadership and demonstrate 
powerful survival impact through the use 
of a clinical quality registry. Our con-
stituents may well ask, “Why aren’t we 
following?”
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To the Editor:
Improving outcomes such as diag-
nosis, staging, and survival in lung 
cancer is the objective of all stake-
holders in what remains a disease 
that is largely treatment resistant. Our 
interest is usually drawn to announce-
ments of development and innovation 
in the fields of diagnostics and thera-
peutics. Few perhaps might anticipate 
that the use of available data may have 
the potential to result in credible and 
substantial improvements in diagno-
sis and staging quality, care provi-
sion, and both short- and longer-term 
survival. This, however, is precisely 
what is offered in the recent report by 
